These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28743750)

  • 1. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis.
    Jayaraman S; Gantz DL; Haupt C; Gursky O
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6507-E6515. PubMed ID: 28743750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve.
    Gursky O
    Curr Atheroscler Rep; 2020 Sep; 22(11):69. PubMed ID: 32968930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model.
    Magy N; Benson MD; Liepnieks JJ; Kluve-Beckerman B
    Amyloid; 2007 Mar; 14(1):51-63. PubMed ID: 17453625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission of systemic AA amyloidosis in animals.
    Murakami T; Ishiguro N; Higuchi K
    Vet Pathol; 2014 Mar; 51(2):363-71. PubMed ID: 24280941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models for reactive amyloidosis.
    Gruys E; Snel FW
    Baillieres Clin Rheumatol; 1994 Aug; 8(3):599-611. PubMed ID: 7954864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic Stability, Oligomerization, and Amyloidogenicity of HDL-Free Serum Amyloid A.
    Colón W; Aguilera JJ; Srinivasan S
    Adv Exp Med Biol; 2015; 855():117-34. PubMed ID: 26149928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the serum amyloid A protein in acute phase plasma high density lipoprotein the precursor of AA amyloid fibrils?
    Baltz ML; Rowe IF; Caspi D; Turnell WG; Pepys MB
    Clin Exp Immunol; 1986 Dec; 66(3):701-8. PubMed ID: 3105937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1.
    Liepnieks JJ; Kluve-Beckerman B; Benson MD
    Biochim Biophys Acta; 1995 Jan; 1270(1):81-6. PubMed ID: 7827140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.
    Srinivasan S; Patke S; Wang Y; Ye Z; Litt J; Srivastava SK; Lopez MM; Kurouski D; Lednev IK; Kane RS; Colón W
    J Biol Chem; 2013 Jan; 288(4):2744-55. PubMed ID: 23223242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties.
    Takase H; Tanaka M; Miyagawa S; Yamada T; Mukai T
    Biochem Biophys Res Commun; 2014 Jan; 444(1):92-7. PubMed ID: 24440699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral proinflammatory cytokine and SAA generation profiles and spatio-temporal relationship between SAA and lysosomal cathepsin B and D in murine splenic monocytoid cells during AA amyloidosis.
    Phipps-Yonas H; Pinard G; Ali-Khan Z
    Scand J Immunol; 2004 Feb; 59(2):168-76. PubMed ID: 14871293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From hexamer to amyloid: marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature.
    Wang L; Lashuel HA; Colón W
    Amyloid; 2005 Sep; 12(3):139-48. PubMed ID: 16194868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of amyloid proteins.
    Benson MD; Kluve-Beckerman B; Liepnieks JJ; Murrell JR; Hanes D; Uemichi T
    Ciba Found Symp; 1996; 199():104-13; discussion 113-8. PubMed ID: 8915606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
    Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
    Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks.
    Frame NM; Gursky O
    FEBS Lett; 2016 Mar; 590(6):866-79. PubMed ID: 26918388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation.
    Noborn F; Ancsin JB; Ubhayasekera W; Kisilevsky R; Li JP
    J Biol Chem; 2012 Jul; 287(30):25669-77. PubMed ID: 22654109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.
    Röcken C; Menard R; Bühling F; Vöckler S; Raynes J; Stix B; Krüger S; Roessner A; Kähne T
    Ann Rheum Dis; 2005 Jun; 64(6):808-15. PubMed ID: 15897303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extracellular chaperone haptoglobin prevents serum fatty acid-promoted amyloid fibril formation of β2-microglobulin, resistance to lysosomal degradation, and cytotoxicity.
    Sultan A; Raman B; Rao CM; Tangirala R
    J Biol Chem; 2013 Nov; 288(45):32326-32342. PubMed ID: 24078632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent insights into the pathogenesis of type AA amyloidosis.
    van der Hilst JC
    ScientificWorldJournal; 2011 Mar; 11():641-50. PubMed ID: 21403980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.